ReviewPubMed ID: 35594621·2022
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Segraves RT, Clayton AH, Croft H, et al.
Sexual Medicine Reviews, 2022
Key finding
PT-141 showed superior efficacy vs flibanserin (RR 1.47, 95% CI 1.12-1.93) but with higher nausea rates (38% vs 11%).
Summary
Network meta-analysis comparing efficacy and safety profiles of FDA-approved HSDD treatments using published trial data.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Journal of Sexual Medicine · 2021 · Human RCT
Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
The Journal of Sexual Medicine · 2021 · Human Pilot
RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
Skin Hyperpigmentation with Melanocortin-4 Receptor Agonists: Predictors and Prevention
The Journal of Sexual Medicine · 2020 · Human Pilot